How to Read Your NIH SBIR Summary Statement: A Complete Guide

SBIR Grant Writers · February 6, 2026

You submitted your NIH SBIR application months ago. Now the summary statement is available in eRA Commons, and you are staring at a document full of scores, critiques, and unfamiliar terminology. Whether the news is good or bad, understanding exactly what the summary statement tells you is the first step toward deciding what to do next.

What is a Summary Statement?

The summary statement is the official written record of how your application was evaluated during peer review. It is prepared after the study section meeting and typically becomes available in eRA Commons within a few weeks of the review date. The document includes several distinct components, each of which tells you something different about how your application was received.

The summary statement is marked "Privileged Communication," which means it is intended solely for the applicant and NIH staff. You should not share it publicly, though you can and should discuss it with collaborators, mentors, and grant writing professionals who are helping you plan next steps.

Understanding the Impact Score

The most prominent number on your summary statement is the overall impact score. This score ranges from 10 (best) to 90 (worst) and represents the consensus of the review panel on the overall merit of your application. The score is calculated by averaging the individual scores (1-9) given by all voting reviewers and multiplying by 10.

Not every application receives an impact score. If your application was triaged - meaning it fell in the lower half of applications reviewed by the panel - it will not be discussed at the meeting and will not receive an impact score. Triaged applications still receive written critiques from the assigned reviewers, but no panel discussion takes place. If your application was triaged, the summary statement will indicate this, and there will be no impact score listed.

Reading the Criterion Scores

Below the impact score, you will find individual criterion scores given by each assigned reviewer. For SBIR applications, these criteria are scored on a 1-9 scale (1 being the best) and typically include five categories.

Criterion	Score Range	What It Measures
Significance	1-3 / 4-5 / 6-9	Does the project address an important problem? Will it improve scientific knowledge or clinical practice?
Investigator(s)	1-3 / 4-5 / 6-9	Are the PIs and team qualified? Do they have the expertise and track record to execute the project?
Innovation	1-3 / 4-5 / 6-9	Does the project use novel approaches? Does it challenge existing paradigms?
Approach	1-3 / 4-5 / 6-9	Is the experimental design sound? Are potential problems addressed? Is the methodology rigorous?
Environment	1-3 / 4-5 / 6-9	Does the institution provide the necessary resources, facilities, and support?

Each assigned reviewer submits their criterion scores independently before the study section meeting. These scores are not discussed or negotiated during the meeting, and they are not mathematically combined to produce the impact score. The impact score is a separate, holistic assessment. This means you can have strong criterion scores and a weaker impact score (or vice versa) depending on how reviewers weighed different factors during discussion.

Decoding the Written Critiques

The written critiques are the most valuable part of the summary statement. Each assigned reviewer (typically two or three) provides a narrative evaluation organized by criterion. Within each criterion, strengths and weaknesses are listed separately.

What to look for in the strengths

Do not skip the strengths. They tell you what is working in your application and what you should preserve in any revision. If a reviewer highlighted your preliminary data, your team composition, or your experimental design as strong, those elements are resonating and should be maintained or even expanded in a resubmission.

What to look for in the weaknesses

Weaknesses fall into several categories, and distinguishing between them is critical for planning your next steps:

• Fatal flaws - These are fundamental problems with the science, design, or feasibility that require major restructuring. If a reviewer identifies a methodological flaw that undermines the entire approach, this cannot be fixed with minor edits.
• Substantive concerns - These are real issues that need to be addressed but do not necessarily invalidate the project. Missing controls, insufficient power analysis, unclear eligibility criteria, or questions about recruitment feasibility fall into this category.
• Clarification requests - Sometimes a reviewer raises something as a weakness that was actually in your application but was not communicated clearly enough. These are often the easiest to fix and the most frustrating to receive.
• Stylistic preferences - Occasionally a reviewer will suggest reorganization or different emphasis that reflects their personal preference rather than a scientific concern. These should be considered but may not require significant changes.

Consensus vs. individual concerns

Pay close attention to issues that multiple reviewers raised independently. If two out of three reviewers flagged the same weakness - for example, concerns about recruitment feasibility or the qualifications of a key team member - that concern carries significant weight and must be addressed thoroughly. A concern raised by only one reviewer may still matter, but a concern raised by multiple reviewers is almost certain to be raised again in a re-review.

The Resume and Summary of Discussion

At the top of the summary statement, you will find a brief paragraph labeled "Resume and Summary of Discussion." This section, written by the Scientific Review Officer (SRO), summarizes the key points raised during the panel discussion. It is particularly important because it captures how the broader panel (not just the assigned reviewers) viewed your application.

If the summary notes a "split" among committee members, that means there was genuine disagreement about the merit of your proposal. This is actually useful information. It tells you that some reviewers saw strong merit in your work, and the challenge is to address the concerns of the skeptics without losing the elements that impressed the supporters.

Additional Review Elements

The summary statement also includes assessments of several additional elements that do not receive numerical scores but can significantly affect your application's fate.

Protection of Human Subjects is evaluated as either Acceptable or Unacceptable. An "Unacceptable" designation is serious - it means the review panel identified problems with your human subjects protections that must be resolved before an award can be made. Common issues include insufficient attention to all participant groups (not just the primary subjects), inadequate informed consent procedures, or incomplete risk-benefit analysis. An Unacceptable designation does not necessarily prevent funding, but it does require that you address the issues to NIH's satisfaction before any award is released.

Commercialization Plan is evaluated for Phase II and Fast-Track applications. Reviewers assess whether you have a credible market analysis, a realistic path to revenue, and the commercial infrastructure to bring your technology to market. Unlike the scored criteria, the commercialization assessment is narrative rather than numerical, but weak commercialization can significantly dampen enthusiasm.

Budget recommendations indicate whether the panel believes your budget is appropriate. "Recommend as Requested" is the best outcome. If the panel recommends budget modifications, the specifics will be noted and NIH grants management staff will adjust accordingly if the application is funded.

What the Scores Really Mean

It helps to understand how reviewers think about the scoring scale, because the numbers alone can be misleading.

Impact Score	General Interpretation	Typical Outcome
10-20	Exceptional. Very few if any weaknesses.	Almost always funded, depending on payline.
21-30	Excellent. Minor weaknesses that do not diminish overall enthusiasm.	Funded at most Institutes in most years.
31-40	Very good. Some notable weaknesses but strong overall merit.	May or may not be funded depending on Institute and payline.
41-50	Good. Significant weaknesses identified alongside genuine strengths.	Unlikely to be funded without resubmission.
51+	Substantial concerns. Major revisions needed.	Not funded. Consider major restructuring before resubmitting.

Deciding Your Next Steps

Once you have thoroughly read and understood your summary statement, the question becomes: what do you do now? The answer depends on your score, your critiques, and your circumstances.

If your score is near or below the payline

Congratulations - your application may be funded. Contact the Program Officer listed on the summary statement to discuss next steps. Be aware that even with a fundable score, there may be administrative requirements to address (such as resolving an Unacceptable human subjects determination or responding to budget recommendations) before an award is made. The Program Officer can tell you what to expect and when.

If your score is close but above the payline

This is the most common scenario for applications that eventually get funded on resubmission. Your application has real merit, but specific weaknesses held it back. Read the critiques carefully, identify every concern, and develop a systematic plan to address each one. NIH allows one resubmission (A1) per application, and you will have a one-page introduction to explain how you addressed the previous review.

If your application was triaged

A triage does not mean your science is bad. It means that in a competitive review environment, your application did not present its case strongly enough to rise above the threshold. Review the written critiques from the assigned reviewers, identify whether the issues are fixable (poor presentation, missing preliminary data, unclear aims) or fundamental (wrong mechanism, weak premise). If the issues are fixable, a well-executed resubmission can succeed. If the issues are fundamental, consider substantially restructuring and submitting as a new application.

If this was already a resubmission

NIH allows only one resubmission per application. If your A1 was not funded, you cannot submit an A2. However, you can submit a new application (with a new application number) that addresses a substantially different set of specific aims. "Substantially different" means more than just rewording - the aims should reflect a meaningfully different approach or scope, even if the underlying technology is the same.

Common Mistakes When Reading Summary Statements

After reviewing thousands of summary statements with our clients, we see the same misinterpretations come up repeatedly.

Focusing only on the score. The score is important, but the critiques tell you what to do about it. Two applications with the same impact score can have completely different paths forward depending on the nature of the weaknesses identified.

Taking it personally. Reviewer comments can feel harsh, especially when they question your expertise or your understanding of the field. Remember that reviewers are evaluating the application, not you. Their job is to identify every potential concern, and they are doing so under time pressure.

Ignoring the strengths. We see applicants immediately focus on weaknesses and overlook the strengths entirely. The strengths tell you what to protect. If you restructure your entire application in response to weaknesses but lose the elements that reviewers praised, you may end up worse off.

Treating all weaknesses equally. A concern about experimental design raised by all three reviewers is categorically different from a suggestion about section organization raised by one reviewer. Prioritize based on how many reviewers raised the issue and how central it is to the science.

Being defensive instead of responsive. In your resubmission introduction, never argue with reviewers. Even if you believe a reviewer misunderstood something, frame your response as additional clarification rather than a correction. Phrases like "We appreciate this concern and have strengthened the proposal by..." are far more effective than "The reviewer was incorrect because..."

When to Call Your Program Officer

Your NIH Program Officer (PO) is listed on the summary statement and is one of your most valuable resources. You should contact your PO in several situations: when your score is near the payline and you want to understand funding likelihood; when you need clarification on whether to resubmit or submit a new application; when the summary statement flags administrative issues you do not fully understand; or when you want feedback on your resubmission strategy before investing months of work.

Program Officers cannot change your score or override the review panel's assessment, but they can provide context, guidance, and strategic advice that helps you make better decisions about your next submission.